Hypoparathyroidism Market is segmented By Treatment (Hormone Replacement Therapy, Adjunctive Therapies), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Specialty Clinics, Homecare Settings), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Million) for the above-mentioned segments.
Market Size in USD
CAGR7.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 7.5% |
Market Concentration | Medium |
Major Players | Takeda Pharmaceutical Company Limited, Ascendis Pharma A/S, Amgen Inc., Entera Bio Ltd., Shire Plc |
The hypoparathyroidism market is estimated to be valued at USD 731.1 Mn in 2024 and is expected to reach USD 1213.4 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031. Advancements in drug research and development have enabled manufactures to explore novel treatment approaches for hypoparathyroidism. Growing access to healthcare infrastructure and services in developing regions is also supporting patients to seek and initiate early treatment.